INCLUSION CRITERIA:

          1. 18 years or over

          2. Written (signed and dated) informed consent and be capable of co-operating with
             treatment and follow-up

          3. Histologically or cytologically proven solid tumours or Multiple Myeloma refractory to
             conventional treatment, or for which no conventional therapy exists or is declined by
             the patient

          4. Life expectancy of at least 12 weeks

          5. World Health Organisation (WHO) performance status of 0 or 1 (Appendix 1)

          6. Measurable and/or evaluable disease according to RECIST 1.1 (appendix 3) for patients
             with solid tumours or according to IMWG (appendix 4) for multiple myeloma patients.

          7. Haematological and biochemical indices within the ranges shown in the protocol. These
             measurements must be performed within one week (Day -7 to Day 1) before the patient is
             entered into the trial.

             ADDITIONAL INCLUSION CRITERIA FOR Part II:

          8. Documented presence of RAS-RAF-MEK pathway mutations including BRAF, KRAS and NRAS. In
             Part IIC at least three patients should have KRAS mutant lung cancer. In Part IID
             expansion, all 10 patients should have RAS mutant cancer.

          9. Patients with multiple myeloma refractory to conventional treatment. Haematological
             indices as in section 4.1.1 above except ANC ≥ 1.0 x 109/L, platelet count ≥ 50 x
             109/L and serum creatinine ≤ 1.5 x (ULN). Patients can be deemed as eligible based on
             serum creatinine alone if creatinine clearance/isotope clearance is deranged.

         10. Archival tumour sections available for patients with solid tumours, or diagnostic bone
             marrow samples available for patients with multiple myeloma.

         11. For patients with solid tumours only: presence of at least one measurable disease
             lesion according to RECIST 1.1.

        EXCLUSION CRITERIA:

          1. Prior chemotherapy, radiotherapy (other than a short cycle of palliative radiotherapy
             for bone pain), or immunotherapy within 28 days of first receipt of study drug (within
             6 weeks for nitrosoureas and mitomycin C), with the exception of Dexamethasone for
             patients with multiple myeloma (see section 5.6). Hormone therapy within 14 days of
             first receipt of study drug, with exception of prostate cancer if indicated.

          2. Ongoing toxic manifestations of previous treatments except Grade 1 toxicities which in
             the opinion of the Investigator should not exclude the patient.

          3. Brain metastases.

          4. Ability to become pregnant (or already pregnant or lactating). However, those female
             patients who have a negative serum or urine pregnancy test before enrolment and agree
             to use two highly effective forms of contraception (oral, injected or implanted
             hormonal contraception and condom, have an intra-uterine device and condom, diaphragm
             with spermicidal gel and condom) for four weeks before entering the trial, during the
             trial and for six months afterwards are considered eligible.

          5. Male patients with partners of child-bearing potential (unless they agree to take
             measures not to father children by using one form of highly effective contraception
             [condom plus spermicide] during the trial and for six months afterwards). Men with
             pregnant or lactating partners should be advised to use barrier method contraception
             (for example, condom plus spermicidal gel) to prevent exposure to the foetus or
             neonate.

          6. Major thoracic or abdominal surgery from which the patient has not yet recovered.

          7. At high medical risk because of non-malignant systemic disease including active
             uncontrolled infection.

          8. Known to be serologically positive for hepatitis B, hepatitis C or human
             immunodeficiency virus (HIV).

          9. Patients with the inability to swallow oral medications or impaired gastrointestinal
             absorption due to gastrectomy or active inflammatory bowel disease.

         10. History of any bowel disease including abdominal fistula, gastro-intestinal
             perforation, and diverticulitis.

         11. Concurrent congestive heart failure, prior history of class III/ IV cardiac disease
             (New York Heart Association [NYHA] - refer to Appendix 5), myocardial infarction
             within the last 6 months, unstable arrhythmias, unstable angina or severe obstructive
             pulmonary disease.

         12. Concurrent ocular disorders:

               1. Patients with history of glaucoma, history of retinal vein occlusion (RVO),
                  predisposing factors for RVO, including uncontrolled hypertension, uncontrolled
                  diabetes, uncontrolled hyperlipidemia, uncontrolled hypercholesterolemia,
                  hyperviscosity syndromes, medically significant history of vasculitis,
                  inflammatory, atherosclerotic or thrombophilic conditions and coagulopathy.

               2. Patient with history of retinal pathology or evidence of visible retinal
                  pathology that is considered a risk factor for RVO, intraocular pressure > 21 mm
                  Hg as measured by tonometry, or other significant ocular pathology, such as
                  anatomical abnormalities that increase the risk for RVO.

               3. Patients with a history of corneal erosion (instability of corneal epithelium),
                  corneal degeneration, active or recurrent keratitis, and other forms of serious
                  ocular surface inflammatory conditions

         13. Patients exposed to CYP3A4 inhibitors within 7 days prior to the first dose (see
             Appendix 6 table for CYP3A4 inhibitors).

         14. Is a participant or plans to participate in another interventional clinical trial,
             whilst taking part in this Phase I study of RO5126766 and/or everolimus. Participation
             in an observational trial would be acceptable.

         15. Any other condition which in the Investigator's opinion would not make the patient a
             good candidate for a clinical trial with RO5126766 e.g. hypersensitivity to RO5126766.

             Part IID specific exclusions:

         16. Has received a live vaccine within 30 days of planned start of study therapy. Note:
             The killed virus vaccines used for seasonal influenza vaccines for injection are
             allowed; however intranasal influenza vaccines (e.g. FluMist®) are live attenuated
             vaccines and are not allowed.

         17. Clinically significant abnormalities of glucose metabolism as defined by any of the
             following:

               -  Diagnosis of diabetes mellitus types I or II (irrespective of management).

               -  Glycosylated haemoglobin (HbA1C) ≥7.0% at screening

               -  Fasting Plasma Glucose ≥ 8.3mmol/L at screening. Fasting is defined as no caloric
                  intake for at least 8 hours.

         18. Any other condition which in the Investigator's opinion would not make the patient a
             good candidate for a clinical trial with Everolimus. Examples of which include:
             hereditary problems of galactose intolerance, Lapp lactase deficiency or
             glucose-galactose malabsorption; hypersensitivity to Everolimus, to other rapamycin
             derivatives or to any of the excipients; pre-existing infections.